Answers are grounded in this paper and cite their sources.
The long-term vascular complications of diabetes include retinopathy, nephropathy, neuropathy and macrovascular disease. The outcomes are: visual impairment and blindness due to diabetic retinopathy renal failure and hypertension due to diabetic nephropathy pain, paraesthesiae, muscle weakness and autonomic dysfunction due to diabetic neuropathy cardiac disease, peripheral vascular disease and stroke due to macrovascular disease Clinically evident diabetes-related vascular complications should be rare in childhood and adolescence. However, early functional and structural abnormalities may be present a few years after the onset of the disease. Childhood and adolescence is a period during which intensive education and treatment may prevent or delay the onset and progression of complications. 1 A. There has been a declining incidence of complications reported in many areas with specialised clinics 2-4. This has occurred over a period of time during which there have been major changes in diabetes management, identification of putative risk factors, and the advent of regular screening for complications. There is no evidence that this is a world-wide occurrence: in areas where health care is not optimal, a greater risk of complications will remains. The Diabetes Control and Complications Trial (DCCT) was a multicentre, randomised controlled clinical trial involving 1441 patients with type 1 diabetes conducted in North America from 1983–1993 5. At recruitment 195 were pubertal adolescents (aged 13–17 years): there were no children 1. After completion of the DCCT (a median in the adolescent group of 7.4 years) and hence the end of randomisation to the two treatment groups (intensive and conventional treatment), the Epidemiology of Diabetes Interventions and Complications (EDIC) study continued to follow patients 6. After 4 years there was no significant difference in HbA1c between the former intensive and conventional treatment groups. The DCCT provided unequivocal evidence that intensive diabetes treatment and improved glycemic control conferred a significant risk reduction for microvascular complications compared with conventional treatment 5A. The EDIC study has shown that this positive effect continued after randomisation, i.e. that there was a memory effect of the improved glycaemic control. In addition it showed a positive effect of intensive therapy for reduction in macrovascular disease 7A. In the adolescent cohort, intensive treatment compared with conventional treatment, reduced the risk and progression of background retinopathy by 53%, clinical neuropathy by 60% and microalbuminuria by 54%. The difference in HbA1c was 8.1 vs 9.8%. The benefits of intensive therapy persisted in the former adolescent cohort during the EDIC study: the previously intensively managed group had 74% less retinopathy, 48% less microalbuminuria and 85% less albuminuria 6. Compared with conventional treatment, intensive treatment in the total age group reduced the risk of clinical neuropathy by 60%. Cardiovascular events were reduced by 50% in the previously intensively treated group compared to the control group during a mean 17 years follow-up 7. The DCCT confirmed that improved glycemic control may initially worsen diabetic retinopathy. However within 1.5 to 3 years, the advantage of intensive treatment is evident 8-10. In the DCCT, the long-term benefits of intensive insulin treatment greatly outweighed the risk of early retinal deterioration. Ophthalmological monitoring is recommended before initiation of intensive treatment and at 3 month intervals for 6–12 months thereafter for patients with long-standing poor glycaemic control, particularly if retinopathy severity is at or past the moderate nonproliferative stage at the time of intensification E. Longer duration of diabetes, older age and puberty are risk factors for complications 11. The prepubertal years of diabetes duration have a significant lesser impact especially further from the onset of gonadarche 12B. For the same diabetes duration, age and puberty increase the risk for retinopathy and elevated AER 13B. Smoking is associated with an increased risk of developing persistent microalbuminuria or macroalbuminuria 4, 14. The evidence for the effect of smoking on retinopathy is less clear. Type 1 diabetes and smoking interact to produce excess cardiovascular morbidity and mortality 15B. Hypertension has a greater impact on cardiovascular disease in diabetic patients than in non-diabetic individuals 16. Blood pressure control (< 130/80 mmHg in adults) is effective in decreasing cardiovascular morbidity and mortality in diabetes 17A. Dyslipoproteinaemia is associated with microalbuminuria and retinopathy development in the DCCT/EDIC 18, 19. This included higher total and LDL cholesterol and higher triglyceride levels for microalbuminuria, as well as larger LDL particle size and apoprotein B in men B. Family history of complications increases the risk for nephropathy 20 and retinopathy 21B. Higher body mass index (BMI) is a risk factor for retinopathy 22, neuropathy 23, microalbuminuria 24 and cardiovascular disease 25B. Life style issues: sedentary men with diabetes have higher mortality than active individuals 26B. Adolescents have a higher risk of progression to vision threatening retinopathy compared to adult patients with diabetes 27, 28. The progression may be rapid, especially in those with poor glycaemic control 29. Hence, adolescence is the time when efforts should be directed to screening for early signs of diabetic retinopathy and modifiable risk factors. Regression of retinopathy can also occur 27, 28, 30. Background retinopathy is characterised by microaneurysms specific to diabetic retinopathy, haemorrhages both pre- and intraretinal, soft and hard exudates involving microinfarction and protein and lipid leakage respectively, intra-retinal microvascular abnormalities and dilatation, constriction and tortuosity of vessels. Background retinopathy is not vision-threatening and does not invariably progress to proliferative retinopathy. Pre-proliferative retinopathy is characterised by vascular obstruction, progressive intra-retinal microvascular abnormalities and infarctions of the retinal nerve fibres causing cotton wool spots. Proliferative retinopathy (PDR) is characterised by neovascularisation in the retina and/or vitreous posterior surface. The vessels may rupture or bleed into the vitreoretinal space which is vision-threatening. Encasement in connective tissue results in adhesions, which can cause haemorrhage and retinal detachment. High-risk characteristics for visual loss are the location and extent of neovascularisation and signs of vitreous or preretinal haemorrhage 31. Maculopathy is characterised by decreased vascular competence and microaneurysm formation which produce exudation and swelling in the central retina. The most sensitive detection methods for retinopathy are stereoscopic fundal photography and fluorescein angiography. 7-field stereoscopic fundus photography provides greater sensitivity for detecting both background and proliferative retinopathy compared with direct ophthalmoscopy 28, 32, 33A. Fluorescein angiography reveals functional abnormalities (vascular permeability) as well as structural abnormalities in the blood vessels whereas fundal photography reveals only structural abnormalities. Other techniques used in the detection of diabetic retinopathy include indirect ophthalmoscopy and monochromatic single-field photography. In adults with diabetes, mydriasis reduced the technical failure rate over nonmydriatic fundal photography but did not improve sensitivity and specificity for detection of diabetic retinopathy or need for referral compared to undilated fundal photography of a single field 34. In an incident cohort, after 6 years duration with HbA1c of 8.7%, 7-field stereoscopic fundal photography detected early retinopathy (1 microaneurysm or haemorrhage) in 8% of children less than 11 years and 12% of prepubertal children. This compares with retinopathy detection in 25 % of adolescents older than 11 years and 29% of pubertal adolescents 13 B. Screening from age 11 years with 2 years diabetes duration or from 9 years with 5 years duration will capture most retinopathy developing in children and adolescents E. Once sight-threatening retinopathy has been detected, the treatment options are limited. Panretinal photocoagulation, commonly known as ‘laser therapy’, consists of multiple discrete outer retinal burns throughout the mid and far peripheral area but sparing the central macula. It has been proven to reduce the progression of visual loss by more than 50% in patients with proliferative retinopathy 31, 35A. However, photocoagulation is not indicated for eyes with mild or moderate nonproliferative retinopathy 36. Side effects of treatment are decreased night and peripheral vision and subtle changes in color perception. Complications of laser therapy are vitreal and choroidal haemorrhages or visual sequelae of misplaced burns. Diabetic nephropathy is defined as persistent proteinuria greater than 500 mg/24 hours or albuminuria greater than 300 mg/24 hours and is usually associated with hypertension, and a diminishing glomerular filtration rate (GFR) 37. End-stage renal failure may occur many years later and requires dialysis or kidney transplantation. Diabetic nephropathy is a major cause of morbidity and mortality amongst young adults with type 1 diabetes 38. Early detection of diabetic nephropathy and timely treatment of blood pressure have a pivotal role in the prevention of end-stage renal failure in young people and adults with diabetes 39 E. The first clinical sign is microalbuminuria. This is defined 37 as any of those below: Albumin excretion rate (AER) between 20 and 200μg/min or AER 30–300 mg/24 h in 24-h urine collections Albumin concentration (AC) 30–300 mg/L (on early morning urine sample) Albumin/creatinine ratio (ACR) 2.5–25 mg/mmol or 30–300 mg/gm (spot urine) in males and 3.5–25 mg/mmol in females (because of lower creatinine excretion) Other definitions have also been used, in longitudinal studies. The relationship between timed overnight urine collections with first morning urine albumin to creatinine ratio has now been determined in children and adolescents by linear regression: AER 20-200ug/min corresponds to ACR of 3.5-35 mg/mmol in males and 4.0-35 mg/mmol for females 16. This also corresponds to 2.4 and 2.2 standard deviations above the mean of the general population. Random ACR are higher by comparison, with first morning ACR of 3 mg/mmol corresponding to 4.5 mg/mmol in males and 5.2 mg/mmol in females 17. Microalbuminuria is confirmed by finding 2 or all of 3 samples abnormal over a 3–6 month period. Persistent microalbuminuria has been shown to predict the progression to end stage renal failure 2, 30, 31, 40-42 and is associated with an increased risk of macrovascular disease 43, 44B. An increase of AER within the microalbuminuric range identifies patients at risk of progression to renal damage 24, 45, 46B. Loss of nocturnal dipping on 24 hour blood pressure monitoring is an early marker of diabetic renal disease, preceding microalbuminuria 47. Microalbuminuria can also regress 48, especially in adolescents 24, 49. Progression to microalbuminuria is preceded by renal hypertrophy 50B. Confounders Exercise increases the albumin excretion rate in the nondiabetic individual and more markedly in diabetes. Even moderate exercise may interfere with the interpretation of data 37. For interpretation of persistently elevated AER values, especially in children with short diabetes duration it is essential to exclude other causes of albuminuria such as IgA or other types of nephritis common in childhood. In an incident cohort, after 6 years duration, early elevation of AER (greater than 7.5μg/min) was detected in 5% of children under 11 years and 5% of prepubertal children: no microalbuminuria was detected. This compared to early elevation of AER in 25% adolescents older than 11 years and 26% of pubertal adolescents. 13. Screening from age 11 years with 2 years diabetes duration and from 9 years with 5 years duration will capture most evolving microalbuminuria in children and adolescents E. Effective antihypertensive therapy in patients with nephropathy prolongs the time to end-stage renal disease 51B. A recent prospective study has shown improved prognosis of renal function from 5 to 7 years from onset of nephropathy to a median of 21.7 years 52, predominantly due to aggressive antihypertensive treatment, with smaller contributions from improved glycaemic control and smoking cessation B. Blood pressure values between the 90th and 95th percentiles are defined as prehypertension 53, 54. Protocols and reference values for 24-h ambulatory blood pressure monitoring in children have also been published 21, 47. Angiotensin converting enzyme inhibitors (ACEI) are recommended for use in children and adolescents with hypertension 55. They have been effective and safe in children in short-term studies 28, 56. The clinical beneficial effect of angiotensin II receptor antagonists in hypertension is similar to that observed with ACEI, but have not been used extensively in children. Angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (AIIRA) reduce progression from microalbuminuria to macroalbuminuria and increase the regression rate to normoalbuminuria 57A. For those with microalbuminuria, ACEI and AIIRA reduce the doubling of serum creatinine. Whilst ACEI reduces all-cause mortality, AIIRA use was associated with higher all-cause mortality compared with placebo A. Despite the above evidence mainly in adults, there are still some concerns regarding the use of ACEI in protecting long-term renal function in young people without hypertension. In meta-analysis of individual patient data, the beneficial effects were more modest in those with the lowest levels of microalbuminuria 58A. Young people with microalbuminuria would potentially be taking ACEI for decades. Side effects include cough, hyperkalaemia, headache and impotence 57. Furthermore an increase in major congenital malformations has recently been reported after first trimester exposure to ACEI but not with other antihypertensive agents in nondiabetic women 59. Diabetes can affect the somatic and autonomic nervous system. The somatic neuropathies associated with diabetes fall into two broad categories: Focal neuropathies include mononeuropathies such as carpal tunnel syndrome, palsy of the peroneal nerve, palsy of the third cranial nerve and proximal nerve conditions (e.g. diabetic amyotrophy). Diabetic sensorimotor polyneuropathy is the most common generalised neuropathy and, for this reason, the simplified term “diabetic neuropathy” is commonly used. It is a polyneuropathy because of the diffuse damage to all peripheral nerve fibres, motor, sensory and autonomic. Such damage occurs insidiously and progressively and is characterised at first by sensory loss and later by loss of motor function, in a stocking and glove distribution. Autonomic neuropathy can cause postural hypotension, vomiting, diarrhoea, bladder paresis, impotence, sweating abnormalities, impaired light reflex, impotence and retrograde ejaculation. Abnormal heart rate responses and prolonged QT intervals have been associated with increased risk of sudden death 60. Clinical assessment involves history taking, especially of numbness, persistent pain or paraesthesia; and physical examination of ankle reflexes, vibration and light touch sensation (by conventional neurological examination or by graduated monofilaments). Autonomic nerve tests include: heart rate response to deep breathing, standing from a lying position, Valsalva Manoeuvre, heart rate variation at rest, QT interval, postural changes in blood pressure and pupillary responses to light and dark adaptation. Peripheral nerve tests include: quantitating vibration and thermal discrimination thresholds and nerve conduction. These are mostly used in research settings. Age- and gender- specific normal ranges need to be applied where relevant when interpreting results. Nerve function test abnormalities have not decreased in an adolescent population in which retinopathy and microalbuminuria have decreased over the same time: peripheral nerve abnormalities actually increased 3. This is likely to be due to the increasing body mass index which has occurred over the same time B. The mortality and morbidity of cardiovascular disease (CVD) are markedly increased in diabetic individuals compared to the nondiabetic population 61B. Hypertension has a greater impact on cardiovascular disease in diabetic patients than in non-diabetic individuals 16. Blood pressure control (< 130/80 mmHg in adults) reduces cardiovascular morbidity and mortality in diabetes 17A. A family history of early cardiovascular disease (before 55 years of age), lipid disturbances, type 2 diabetes, hypertension 10 and smoking place the individual with diabetes at higher risk B. Atherosclerosis starts in childhood and adolescence as shown by intima-media thickness of the carotids and aorta 62 and silent coronary atherosclerosis measured by intravascular ultrasound in young adults with childhood onset diabetes 9B. Silent coronary atherosclerosis 99 and cardiovascular events 7 are strongly associated with poor glycemic control. A. Cholesterol plays an important role in the initiation and progression of atherosclerosis 53. Well-controlled type 1 diabetes is not associated with gross blood lipid disturbances, but more advanced lipoprotein subclass examinations reveal atherogenic profiles 18. Poor glycaemic control was associated with a potentially more atherogenic lipoprotein profile 63. Changes in lipids associated with increased cardiovascular risk are also associated with central obesity in type 1 diabetes (as well as type 2 diabetes) 64. Individuals with type 1 diabetes are as much at risk for hypercholesterolemia as the nondiabetic population. The prevalence approached 50% of young adults in one study 65. The prevalence of elevated non-HDL cholesterol was 25% in a study of individuals less than 21 years of age with type 1 diabetes 66. In adults statins are effective in the primary and secondary prevention of major cardiovascular events, stroke and limb re-vascularisation in patients with diabetes 67A. The Heart Protection Study was a 5 year interventional study of 5963 patients with diabetes, 10% of whom had type 1 diabetes. This effect was independent of glycaemic control and cholesterol levels. Short-term trials have shown that simvastatin, lovastatin and pravastatin are effective and safe in children and adolescents 68-70. No significant side effects were observed in terms of growth, pubertal Tanner grading, testicular volume, menarche, endocrine function parameters, or liver or muscle enzymes. The efficacy and safety of statins in children with type 1 diabetes still need to be determined in randomised trials, as does the age at which treatment should be initiated. Special attention should be paid to symptoms associated with muscles and connective tissues, as there is an increased risk of rhabdomyolysis 71. Screening for diabetes complications aims to detect subclinical complications which may be treated to delay progression to clinical disease Improvement in glycaemic control will reduce the risk for onset and progression of diabetes vascular complications A. Initial eye examination should occur shortly after diagnosis to detect cataracts or major refractive errors which require treatment for binocular vision E. Screening for retinopathy and microalbuminuria should start from 11 years with two years diabetes duration and from 9 years with 5 years duration and after 2 years diabetes duration in an adolescent 13E. Minimum assessment for retinopathy should be by ophthalmoscopy by an E. The of retinopathy screening in general should occur but should be more if there are risk for visual For those with duration less than 10 years, background retinopathy on fundal photography and glycaemic control, assessment by fundal photography can occur treatment reduces the rate of visual loss for vision-threatening retinopathy A. screening for should be by any of the methods 13 morning urine samples ratio (ACR) urine collections overnight urine collections are for adolescents and are less to the effects of exercise and of 2 of 3 collections should be used as evidence of microalbuminuria. Confounders are exercise and Abnormal screening tests should be as microalbuminuria may and not be persistent microalbuminuria is screening for retinopathy, neuropathy and lipid abnormalities is also recommended E. ACEI are recommended for use in children with hypertension They have been effective and safe in children in short-term studies 28, but are not safe during or AIIRA agents should be used in patients with persistent microalbuminuria to prevent progression to in adolescents. Blood pressure should be measured at of hypertension may be by 24-h ambulatory blood pressure E. Blood pressure values should be compared with 55. Blood pressure should be at less than the 95th for age as in all children with hypertension Screening for blood lipids should be after diagnosis diabetes in all children with type 1 diabetes over years E. normal results are this should be 5 there is a family history of early or if the family history is screening should start at 2 years of age for LDL cholesterol should be lower than to improve control and changes lower to statins should be long-term safety is not of smoking will reduce progression of microalbuminuria and cardiovascular disease
No takes yet. Share an insight, caveat, or question.
Donaghue et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: